Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluation

This publication has 13 references indexed in Scilit:

• Effects of a new cardiotonic agent, MDL-17,043, on myocardial contractility and left ventricular performance in congestive heart failure
  American Heart Journal, 1985
• Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failure
  Journal of the American College of Cardiology, 1985
• Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement.
  Circulation, 1985
• Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure
  American Heart Journal, 1984
• Intravenous and oral MDL 17043 (A new inotrope-vasodilator agent) in congestive heart failure: Hemodynamic and clinical evaluation in 38 patients
  Journal of the American College of Cardiology, 1984
• Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failure
  Journal of the American College of Cardiology, 1984
• Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance
  The American Journal of Cardiology, 1984
• Hemodynamic Effects of MDL 17,043, a New Cardiotonic Agent, in Patients with Congestive Heart Failure
  Journal of Cardiovascular Pharmacology, 1983
• Characterization of the Cardiovascular Activities of a New Cardiotonic Agent, MDL 17043 (1,3-Dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one)
  Journal of Cardiovascular Pharmacology, 1982
• Cardiovascular Properties of a New Cardiotonic Agent
  Journal of Cardiovascular Pharmacology, 1982